Michael Tucciarone, MD
Interventional Cardiology · Rochester, MINPI 1427267525
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Edwards Lifesciences at 30.0% of the total. 2025 is the largest year on record at $6,962, 2.8 times the $2,482 reported in 2019.
Across 408 payments — averaging $48.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Boston Scientific$3K
- Medtronic$3K
- Abiomed$2K
- Abbott$979
- Inari Medical, Inc.$964
- plus $4K from 32 others
What the payments were for
- Consulting fees$4502%
- Travel & lodging$7,53938%
- Food & beverage$11,91960%
- Education$600%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 81 | $5,998 |
| Boston Scientific | 34 | $2,908 |
| Medtronic(2 entities) | 30 | $2,846 |
| Abiomed | 87 | $1,986 |
| Abbott | 17 | $979 |
| Inari Medical, Inc. | 20 | $964 |
| Cardiovascular Systems Inc. | 7 | $864 |
| Amgen | 21 | $579 |
| Merck | 13 | $307 |
| Imperative Care, Inc | 4 | $261 |
| Boehringer Ingelheim | 12 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $235 |
| Stryker | 5 | $188 |
| Intact Vascular, Inc. | 2 | $175 |
| Novartis | 7 | $142 |
| Atricure, Inc. | 1 | $134 |
| Alnylam Pharmaceuticals Inc. | 8 | $126 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $106 |
| Bayer | 5 | $105 |
| Cordis US CORP. | 5 | $84 |
| Pfizer | 4 | $82 |
| Heartflow, Inc. | 3 | $79 |
| Kestra Medical Technology Services, Inc. | 2 | $64 |
| Johnson & Johnson | 2 | $63 |
| Chiesi USA, Inc. | 3 | $60 |
| AstraZeneca | 4 | $57 |
| Novo Nordisk | 2 | $42 |
| Teleflex LLC | 2 | $39 |
| Philips North America LLC | 1 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Shockwave Medical, Inc | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Cvrx, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Veryan Medical Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$2,019
- COREVALVE EVOLUT R$1,758
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,307
- Coronary Orbital Atherectomy System$720
- SAPIEN 3 Ultra RESILIA$579
- Impella$525
- FLOWTRIEVER CATHETER, S$502
- CT THROMBECTOMY SYSTEM KIT$502
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$450
- Repatha$354
- SYNERGY$268
- Tack Endovascular System$160
- INSPIRIS RESILIA aortic valve$158
- ABSOLUTE PRO$152
- AVVIGO Guidance System$149
- SYMPHONY CATHETER$144
- HeartMate 3 Left Ventricular Assist Device$138
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$134
- ATRICLIP LAA EXCLUSION SYSTEM$134
- Xience Sierra Coronary Stent$115
How this compares
$19,967 in reported general payments places this provider in the 75th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,141 | $1,498,978 |
| XareltoRivaroxaban | 262 | $359,733 |
| VyndamaxTafamidis | 12 | $281,387 |
| Repatha SureclickEvolocumab | 284 | $214,974 |
| EntrestoSacubitril/Valsartan | 134 | $194,676 |
| JardianceEmpagliflozin | 77 | $105,602 |
| BrilintaTicagrelor | 62 | $61,733 |
| Metoprolol Succinate | 1,517 | $29,904 |
| Isosorbide Dinitrate | 225 | $18,075 |
| Flecainide Acetate | 282 | $15,891 |
| Valsartan | 278 | $15,041 |
| ClopidogrelClopidogrel Bisulfate | 677 | $13,172 |
| Atorvastatin Calcium | 857 | $12,844 |
| Ranolazine ErRanolazine | 100 | $9,848 |
| Losartan Potassium | 627 | $8,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $82 | $1,780,3651,153 claims |
| Johnson & JohnsonXarelto | $63 | $359,733262 claims |
| NovartisEntresto | $142 | $194,676134 claims |
| Boehringer IngelheimJardiance | $244 | $105,60277 claims |
| AstraZenecaBrilinta | $57 | $61,73362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Rochester
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
- Khaldoon AlaswadDetroit$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.